What is Revelation Biosciences's earnings per share (EPS)?

Revelation Biosciences (REVB) reported diluted earnings per share of $-23.95 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Revelation Biosciences Financials

REVB

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Revelation Biosciences (REVB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Revelation Biosciences passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.93x

For every $1 of reported earnings, Revelation Biosciences generates $0.93 in operating cash flow (-$8.3M OCF vs -$8.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$9.0M

YoY-13.8%

Revelation Biosciences's EBITDA was -$9.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.8% from the prior year.

Net Income

-$8.9M

YoY+40.7%

Revelation Biosciences reported -$8.9M in net income in fiscal year 2025. This represents an increase of 40.7% from the prior year.

EPS (Diluted)

$-23.95

Revelation Biosciences earned $-23.95 per diluted share (EPS) in fiscal year 2025. This represents an increase of 97.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$10.7M

YoY+64.6%

5Y CAGR+290.8%

Revelation Biosciences held $10.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Revelation Biosciences had 2M shares outstanding in fiscal year 2025. This represents an increase of 3539.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-100.6%

YoY+218.8pp

5Y CAGR-52.8pp

Revelation Biosciences's ROE was -100.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 218.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$4.1M

YoY+14.5%

Revelation Biosciences invested $4.1M in research and development in fiscal year 2025. This represents an increase of 14.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

REVB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.1M+14.5%	$3.5M-14.4%	$4.1M-22.9%	$5.4M-22.2%	$6.9M	N/A
SG&A Expenses	$5.0M+13.1%	$4.4M-1.9%	$4.5M-17.8%	$5.5M+9.0%	$5.0M+3361.2%	$145K
Operating Income	-$9.1M-13.7%	-$8.0M+7.9%	-$8.7M+20.3%	-$10.9M+9.1%	-$12.0M	N/A
Interest Expense	N/A	N/A	N/A	N/A	$42K	N/A
Income Tax	$0	$0	$0	$0	$0	N/A
Net Income	-$8.9M+40.7%	-$15.0M-12405.6%	-$120K+98.9%	-$10.8M+9.7%	-$12.0M-635.2%	-$1.6M
EPS (Diluted)	$-23.95	$-1052.16-12366.4%	$-8.44	$-149.20	$-42.50	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$923K-30.0%	$1.3M+53.5%	$859K	N/A	$831K-40.4%	$1.4M+94.4%	$718K
SG&A Expenses	N/A	$1.0M-10.8%	$1.1M-7.5%	$1.2M	N/A	$966K-14.3%	$1.1M-4.8%	$1.2M
Operating Income	N/A	-$1.9M+21.1%	-$2.5M-17.5%	-$2.1M	N/A	-$1.8M+28.8%	-$2.5M-32.6%	-$1.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	N/A	$0	N/A	$0	$0	$0
Net Income	N/A	-$1.9M+22.0%	-$2.4M-19.2%	-$2.1M	N/A	-$2.2M+73.3%	-$8.4M-212.9%	-$2.7M
EPS (Diluted)	N/A	$-1.77	$-7.01-232.2%	$-2.11	N/A	$-40.15+83.7%	$-246.27-525.5%	$-39.37

REVB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$11.6M+74.9%	$6.6M-45.8%	$12.2M+121.9%	$5.5M+169.5%	$2.0M-97.2%	$74.2M
Current Assets	$10.8M+64.7%	$6.6M-46.0%	$12.1M+124.4%	$5.4M+183.1%	$1.9M+193.6%	$651K
Cash & Equivalents	$10.7M+64.6%	$6.5M-45.8%	$12.0M+128.3%	$5.3M+312.1%	$1.3M+10763.6%	$12K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.7M+42.2%	$1.9M-65.6%	$5.6M+25.0%	$4.5M+107.8%	$2.1M-97.0%	$70.8M
Current Liabilities	$2.0M+4.4%	$1.9M-65.6%	$5.6M+25.0%	$4.5M+107.8%	$2.1M-37.6%	$3.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.9M+88.2%	$4.7M-29.2%	$6.6M+531.6%	$1.1M+1158.1%	-$99K-102.9%	$3.4M
Retained Earnings	-$49.4M-22.0%	-$40.5M-59.1%	-$25.5M-0.5%	-$25.3M-74.6%	-$14.5M-155.0%	-$5.7M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$11.6M-9.9%	$12.9M+138.3%	$5.4M+35.9%	$4.0M-40.0%	$6.6M-1.8%	$6.7M-45.1%	$12.3M-16.5%	$14.7M
Current Assets	$10.8M-15.7%	$12.8M+139.4%	$5.4M+36.5%	$3.9M-40.2%	$6.6M-1.4%	$6.7M-45.4%	$12.2M-16.6%	$14.6M
Cash & Equivalents	$10.7M-15.8%	$12.7M+145.6%	$5.2M+39.7%	$3.7M-43.0%	$6.5M-0.6%	$6.5M-45.8%	$12.1M-17.0%	$14.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.7M+46.8%	$1.9M+18.2%	$1.6M+44.0%	$1.1M-43.1%	$1.9M-52.9%	$4.1M-63.5%	$11.1M+112.9%	$5.2M
Current Liabilities	$2.0M+7.7%	$1.9M+18.2%	$1.6M+44.0%	$1.1M-43.1%	$1.9M-52.9%	$4.1M-63.5%	$11.1M+112.9%	$5.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.9M-19.5%	$11.0M+187.6%	$3.8M+32.8%	$2.9M-38.8%	$4.7M+76.1%	$2.7M+134.4%	$1.1M-88.0%	$9.5M
Retained Earnings	-$49.4M-5.4%	-$46.9M-4.2%	-$45.0M-5.7%	-$42.6M-5.1%	-$40.5M-4.5%	-$38.8M-6.1%	-$36.5M-29.8%	-$28.1M

REVB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$8.3M+54.9%	-$18.3M-151.4%	-$7.3M+35.1%	-$11.2M-1.2%	-$11.1M-5018.8%	-$217K
Capital Expenditures	N/A	$19K	N/A	N/A	$132K	N/A
Free Cash Flow	N/A	-$18.3M	N/A	N/A	-$11.2M	N/A
Investing Cash Flow	N/A	-$19K	N/A	N/A	-$132K+99.8%	-$74.0M
Financing Cash Flow	$12.5M-2.9%	$12.8M-8.4%	$14.0M-7.7%	$15.2M+89.9%	$8.0M-89.2%	$74.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$35.5M	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$2.0M-23.8%	-$1.6M+17.2%	-$1.9M+31.3%	-$2.8M+25.4%	-$3.7M+59.5%	-$9.3M-273.5%	-$2.5M+12.7%	-$2.8M
Capital Expenditures	N/A	N/A	N/A	N/A	-$18K-200.0%	$18K	$0-100.0%	$19K
Free Cash Flow	N/A	N/A	N/A	N/A	-$3.8M+59.4%	-$9.3M-274.2%	-$2.5M+13.2%	-$2.9M
Investing Cash Flow	N/A	N/A	N/A	N/A	$18K+200.0%	-$18K	$0+100.0%	-$19K
Financing Cash Flow	-$41K-100.5%	$9.1M	N/A	N/A	$3.7M-1.5%	$3.7M	$0-100.0%	$5.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

REVB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-100.6%+218.8pp	-319.4%-317.6pp	-1.8%+1027.2pp	-1029.0%	N/A	-47.8%
Return on Assets	-77.0%+150.1pp	-227.1%-226.1pp	-1.0%+195.8pp	-196.8%+390.2pp	-587.0%-584.8pp	-2.2%
Current Ratio	5.41+2.0	3.43+1.2	2.18+1.0	1.22+0.3	0.89+0.7	0.19
Debt-to-Equity	0.31-0.1	0.41-0.4	0.84-3.4	4.23+25.8	-21.53-42.3	20.74
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-17.3%+46.6pp	-63.9%+7.3pp	-71.2%	N/A	-83.8%+651.8pp	-735.7%-707.4pp	-28.3%
Return on Assets	N/A	-14.8%+30.5pp	-45.3%+6.3pp	-51.7%	N/A	-33.3%+35.1pp	-68.4%-50.1pp	-18.2%
Current Ratio	5.41-1.5	6.92+3.5	3.42-0.2	3.61+0.2	3.43+1.8	1.64+0.5	1.10-1.7	2.80
Debt-to-Equity	0.31+0.1	0.17-0.2	0.41+0.0	0.38-0.0	0.41-1.1	1.52-8.2	9.76+9.2	0.55
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Qualigen Therapeutics Inc QLGN

$6.5M

Galecto Inc. GLTO

$1.7B

Entero Therapeutics ENTO

$10.1M

Silexion Therapeutics Corp SLXN

$3.9M

Frequently Asked Questions

Is Revelation Biosciences profitable?

No, Revelation Biosciences (REVB) reported a net income of -$8.9M in fiscal year 2025.

What is Revelation Biosciences's EBITDA?

Revelation Biosciences (REVB) had EBITDA of -$9.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Revelation Biosciences's return on equity (ROE)?

Revelation Biosciences (REVB) has a return on equity of -100.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Revelation Biosciences's operating cash flow?

Revelation Biosciences (REVB) generated -$8.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Revelation Biosciences's total assets?

Revelation Biosciences (REVB) had $11.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Revelation Biosciences spend on research and development?

Revelation Biosciences (REVB) invested $4.1M in research and development during fiscal year 2025.

How many shares does Revelation Biosciences have outstanding?

Revelation Biosciences (REVB) had 2M shares outstanding as of fiscal year 2025.

What is Revelation Biosciences's current ratio?

Revelation Biosciences (REVB) had a current ratio of 5.41 as of fiscal year 2025, which is generally considered healthy.

What is Revelation Biosciences's debt-to-equity ratio?

Revelation Biosciences (REVB) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Revelation Biosciences's return on assets (ROA)?

Revelation Biosciences (REVB) had a return on assets of -77.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Revelation Biosciences's cash runway?

Based on fiscal year 2025 data, Revelation Biosciences (REVB) had $10.7M in cash against an annual operating cash burn of $8.3M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Revelation Biosciences's Piotroski F-Score?

Revelation Biosciences (REVB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Revelation Biosciences's earnings high quality?

Revelation Biosciences (REVB) has an earnings quality ratio of 0.93x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.